Dynavax (NASDAQ: DVAX) reported Q3 EPS of $0.21, $0.08 better than the analyst estimate of $0.13. Revenue for the quarter came in at $94.9 million versus the consensus estimate of $94.41 million.

FULL YEAR 2025 FINANCIAL GUIDANCE
Dynavax is providing full year 2025 financial guidance, based on its current operating plan:

HEPLISAV-B net product revenue is expected in the range of $315 to $325 million.
Adjusted EBITDA* is expected to be at least $80 million, an increase compared to the prior guidance of at least $75 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.